About Icosavax
Icosavax is a company based in Seattle (United States) founded in 2017 by Adam Simpson was acquired by Astrazeneca in December 2023. Icosavax has raised $152 million across 3 funding rounds from investors including Astrazeneca, Citadel and Janus Henderson Investors. The company has 60 employees as of December 31, 2022. Icosavax operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Seattle, United States
- Employees 60 as on 31 Dec, 2022
- Founders Adam Simpson
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Icosavax, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$152 M (USD)
in 3 rounds
-
Latest Funding Round
$100 M (USD), Series B
Apr 07, 2021
-
Investors
Astrazeneca
& 13 more
-
Employee Count
60
as on Dec 31, 2022
-
Acquired by
Astrazeneca
(Dec 12, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Icosavax
Unlock access to complete
Unlock access to complete
Funding Insights of Icosavax
Icosavax has successfully raised a total of $152M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Icosavax
Icosavax has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Citadel and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital firm
|
Locked | Locked | Locked |
Investor details for Icosavax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Icosavax
Investment portfolio details for Icosavax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Icosavax
Detailed financials for Icosavax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Icosavax Comparisons
Peer comparison for Icosavax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Icosavax
Icosavax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Icosavax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Icosavax
Complete news archive for Icosavax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Icosavax
Icosavax was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Icosavax is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Adam Simpson is the current CEO of Icosavax. They have also founded this company.
Icosavax is a funded company, having raised a total of $152M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Icosavax is 60.
Developer of computationally designed VLP vaccines for treating multiple infections. The company licensed technology offers proteins that can self-assemble into virus-like particles (VLPs), for its leading candidate IVX-121, which is a vaccine for the respiratory syncytial virus and leading to improved neutralizing responses in humans. The company is also working on RSV and SARS-CoV-2 vaccine development.
Icosavax's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Icosavax has 14 investors. Key investors include Astrazeneca, Citadel, Janus Henderson Investors, RA Capital, and Qiming Venture Partners.